Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) EBITDA (2020 - 2025)

Candel Therapeutics' EBITDA history spans 4 years, with the latest figure at -$10.3 million for Q4 2023.

  • On a quarterly basis, EBITDA fell 27.37% to -$10.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$38.4 million, a 10.57% decrease, with the full-year FY2025 number at -$48.3 million, down 44.63% from a year prior.
  • EBITDA hit -$10.3 million in Q4 2023 for Candel Therapeutics, down from -$8.9 million in the prior quarter.
  • Over the last five years, EBITDA for CADL hit a ceiling of $1.6 million in Q4 2021 and a floor of -$17.1 million in Q2 2021.
  • Historically, EBITDA has averaged -$8.3 million across 4 years, with a median of -$8.9 million in 2022.
  • Biggest five-year swings in EBITDA: surged 115.16% in 2021 and later tumbled 607.58% in 2022.
  • Tracing CADL's EBITDA over 4 years: stood at -$10.5 million in 2020, then surged by 115.16% to $1.6 million in 2021, then tumbled by 607.58% to -$8.1 million in 2022, then decreased by 27.37% to -$10.3 million in 2023.
  • Business Quant data shows EBITDA for CADL at -$10.3 million in Q4 2023, -$8.9 million in Q3 2023, and -$9.6 million in Q2 2023.